ASCO 2020 - Chicago - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - May 29- 31, 2020 and August 8-10 , Virtual Program
VIDEOS
Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
June 11-21, 2020, The ASCO Post
What Dose of Ponatinib Is Both Safe and Effective to Treat CML?
June 3, 2020, CheckRare
OncLive News Network On Location: ASCO 2020 Day 1
May 30, 2020, OncLiveTV
Welcome to ASCO 2020
May 15, 2020, Eli Lilly and Company
Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
June 11-21, 2020, The ASCO Post
What Dose of Ponatinib Is Both Safe and Effective to Treat CML?
June 3, 2020, CheckRare
OncLive News Network On Location: ASCO 2020 Day 1
May 30, 2020, OncLiveTV
Welcome to ASCO 2020
May 15, 2020, Eli Lilly and Company
SOME INTERESTING ABSTRACTS ABOUT CML
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study.
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study
Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).
Induction and maintenance for chronic myeloid leukemia-chronic phase: A novel treatment strategy
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study.
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study
Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).
Induction and maintenance for chronic myeloid leukemia-chronic phase: A novel treatment strategy